Standardization of Suspension and Imaging Mass Cytometry Single-Cell Readouts for Clinical Decision Making

Area of Science:

• Biotechnology
• Proteomics
• Cancer Research

Background:

• Mass cytometry, including suspension and imaging techniques, offers single-cell proteomic analysis for tissue characterization.
• Clinical application of mass cytometry requires robust data consistency over time, with limited existing data.

Purpose of the Study:

• To develop and validate experimental and computational pipelines for standardized mass cytometry within a clinical trial setting.
• To assess and correct for batch effects in mass cytometry data over a one-year period.
• To demonstrate the clinical utility of reproducible mass cytometry for guiding cancer treatment decisions.

Main Methods:

• Utilized frozen antibody panels to minimize batch effects between experiments.
• Incorporated well-characterized reference samples for batch effect assessment and correction.
• Systematically evaluated a test tumor sample across multiple runs to confirm batch correction efficacy.

Main Results:

• Developed pipelines within the Tumor Profiler clinical study for advanced cancer patients.
• Batch correction approach consistently reduced signal variations in test tumor samples.
• Demonstrated reproducible and robust proteomic data meeting clinical requirements.

Conclusions:

• Standardized suspension and imaging mass cytometry generate reliable data suitable for clinical use.
• The developed pipelines provide oncologists with critical insights into patient tumor biology.
• These methods support data-driven treatment decisions in advanced cancer care.